<?xml version="1.0" encoding="UTF-8"?>
<NDC>
<NDCCode>
63323-599-30
</NDCCode>
<PackageDescription>
1 VIAL in 1 BOX (63323-599-30) / 21.1 mL in 1 VIAL
</PackageDescription>
<NDC11Code>
63323-0599-30
</NDC11Code>
<ProductNDC>
63323-599
</ProductNDC>
<ProductTypeName>
HUMAN PRESCRIPTION DRUG
</ProductTypeName>
<ProprietaryName>
Deferoxamine
</ProprietaryName>
<ProprietaryNameSuffix/>
<NonProprietaryName>
Deferoxamine Mesylate
</NonProprietaryName>
<DosageFormName>
INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
</DosageFormName>
<RouteName>
INTRAMUSCULAR; INTRAVENOUS; SUBCUTANEOUS
</RouteName>
<StartMarketingDate>
20091215
</StartMarketingDate>
<EndMarketingDate/>
<MarketingCategoryName>
ANDA
</MarketingCategoryName>
<ApplicationNumber>
ANDA078718
</ApplicationNumber>
<LabelerName>
Fresenius Kabi USA, LLC
</LabelerName>
<SubstanceName>
DEFEROXAMINE MESYLATE
</SubstanceName>
<StrengthNumber>
95
</StrengthNumber>
<StrengthUnit>
mg/mL
</StrengthUnit>
<Pharm_Classes>
Iron Chelating Activity [MoA], Iron Chelator [EPC]
</Pharm_Classes>
<DEASchedule/>
<Status>
Active
</Status>
<LastUpdate>
2025-04-02
</LastUpdate>
<PackageNdcExcludeFlag>
N
</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>
N
</ProductNdcExcludeFlag>
<ListingRecordCertifiedThrough>
20261231
</ListingRecordCertifiedThrough>
<StartMarketingDatePackage>
20091215
</StartMarketingDatePackage>
<EndMarketingDatePackage/>
<SamplePackage>
N
</SamplePackage>
</NDC>